Press Releases
Ascendis Pharma Selects PANTHERx® Rare for the Distribution of YORVIPATH® (palopegteriparatide)
December 6, 2024
PITTSBURGH – PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce it is partnering with Ascendis Pharma for the distribution of YORVIPATH®, a FDA approved parathyroid hormone...
Read MoreBridgeBio Selects PANTHERx® Rare Specialty Pharmacy for Distribution of Attruby™ (acoramidis)
November 25, 2024
PITTSBURGH – PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce that it was selected by BridgeBiofor the distribution of Attruby™ (acoramidis), a high-affinity transthyretin...
Read MorePANTHERx® Rare Selected by Calliditas Therapeutics as Specialty Pharmacy for TARPEYO®
September 3, 2024
PITTSBURGH – PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce that it was selected by Calliditas Therapeutics for the exclusive distribution of TARPEYO® (budesonide) delayed...
Read MoreUpsher-Smith Laboratories, LLC Selects PANTHERx® Rare for the Distribution of TORPENZ™ (everolimus) Tablets
August 20, 2024
PITTSBURGH – PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce it was selected by Upsher-Smith Laboratories, LLC for the distribution of TORPENZ™ (everolimus) Tablets for...
Read MorePANTHERx® Rare Partnering with Gilead Sciences, Inc. for the Distribution of LIVDELZI®
August 16, 2024
PITTSBURGH – PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce it is partnering with Gilead Sciences, Inc. for the distribution of a novel selective peroxisome proliferator-activated...
Read MorePANTHERx® Rare Partnering with ITF Therapeutics LLC for U.S. Distribution of DUVYZAT™
July 30, 2024
PITTSBURGH – PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce it is partnering with ITF Therapeutics LLC for the U.S. distribution of DUVYZAT™ (givinostat), the first nonsteroidal...
Read MoreNo posts found